Video Shorts

Wherever possible all patients with prostate cancer should undergo both germinal and somatic BRCA mutation testing as they represent predictive biomarkers of greater sensitivity to treatment with PARP inhibitors.

Tissue-agnostic treatment based on shared genetic aberrations have provided a new direction in cancer treatment. Emerging clinical evidence indicates that many molecular aberrations can be common across tumor types with different site of origin.

Average at diagnosis of prostate cancer is ~65 years & patients usually have multiple co- morbidities and may be on treatment with multiple prescribed medications.

For relapsed and refractory multiple myeloma, use of pomalidomide often in combination with dexamethasone or other agents is recommended in patients who have failed at least two prior treatments, including lenalidomide and a proteasome inhibitor.

Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.

ASCO GU 2022 had 4 important clinical trials in prostate cancer discussed in plenary session as follows.

Several studies carried out by institutions of repute have shown that Dasatinib 50 mg is as effective as 100 mg with less side effects.

High risk disease is observed in 30% of Myeloma Cases. Identification of high-risk patients is important as proportion of high-risk cases increase with relapses and can lead to significant mortality.

Metastatic Triple Negative Breast Cancer is still an unmet medical need.

Anemia is common feature of MDS with 90% patients having anemia at diagnosis or initial presentation. Anemia not only impacts quality of life but is also prognostic in nature.